HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
N-acetylmelphalan
RN given refers to (DL)-isomer
Also Known As:
N-AcMEL; N-acetylmelphalan, (D)-isomer
Networked:
4
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Hydrocarbons: 1713
Halogenated Hydrocarbons: 42
Mustard Compounds: 3
Nitrogen Mustard Compounds: 2
Melphalan: 4353
N-acetylmelphalan: 4
Amino Acids, Peptides, and Proteins: 1
Amino Acids: 30675
Cyclic Amino Acids: 3
Aromatic Amino Acids: 467
Phenylalanine: 4090
Melphalan: 4353
N-acetylmelphalan: 4
Related Diseases
1.
Neoplasms (Cancer)
07/01/1988 - "
This and other experiments indicated that the antitumor effect and tumor localization of N-AcMEL-MoAb conjugates can be enhanced in vivo by rTNF-alpha, thereby enabling successful eradication of larger established subcutaneous murine tumors.
"
01/01/1987 - "
In addition, N-AcMEL-MoAb conjugates more effectively erradicated tumors in vivo than does free MEL or N-AcMEL.
"
01/01/1987 - "
To overcome these nonspecific effects N-acetyl melphalan (N-AcMEL) was synthesized and found to be 75 times less toxic to tumor cells in vitro.
"
07/01/1988 - "
To potentiate the antitumor effect of the N-AcMEL-MoAb conjugate, studies were undertaken to analyze its action in combination with recombinant human tumor necrosis factor alpha (rTNF-alpha), a monokine, capable of causing acute necrosis of syngeneic tumor transplants in mice.
"
09/01/1989 - "
Melphalan (MEL), an alkylating agent, has been modified to a derivative, N-acetylmelphalan (N-AcMEL), which can be conjugated to anticolon cancer monoclonal antibodies (MoAbs 30.6, I-1, and JGT) and used for immunochemotherapy.
"
2.
Necrosis
07/01/1988 - "
To potentiate the antitumor effect of the N-AcMEL-MoAb conjugate, studies were undertaken to analyze its action in combination with recombinant human tumor necrosis factor alpha (rTNF-alpha), a monokine, capable of causing acute necrosis of syngeneic tumor transplants in mice.
"
3.
Colorectal Neoplasms (Colorectal Cancer)
09/01/1989 - "
In a phase I clinical study, N-AcMEL-MoAb conjugates were administered via the hepatic artery to 10 patients, nine of whom had disseminated colorectal cancer (including the liver) and one of whom had Dukes' C colon cancer that had been resected.
"
12/01/1990 - "
Human anti-mouse antibody (HAMA) response was determined in the serum of 67 patients who received subcutaneously administered radiolabelled murine monoclonal antibodies (MoAb) (50 micrograms-3 mg) for immunolymphoscintigraphy and of 10 patients with advanced colorectal cancer who received murine MoAb-N-acetyl melphalan (MoAb-N-AcMEL) conjugates (amount of MoAb ranged from 120 mg/m2 body surface area to 1000 mg/m2 body surface area) as therapy.
"
4.
Thymoma (Thymic Carcinoma)
07/01/1988 - "
N-Acetyl-melphalan-MoAb (N-AcMEL-MoAb) conjugates have previously been shown to have greater antitumor activity than N-AcMEL, melphalan, or MoAb alone against both subcutaneous and ascites murine thymomas in mice (1).
"
5.
Serum Sickness
12/01/1990 - "
Further administration of MoAb-N-AcMEL conjugates to a patient, who had already developed HAMA, led to 'serum sickness'-type symptoms and a transient reduction in the HAMA titres.
"
Related Drugs and Biologics
1.
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.
Melphalan (Alkeran)
3.
Monoclonal Antibodies
4.
N-acetylmelphalan
5.
Alkylating Agents
Related Therapies and Procedures
1.
Therapeutics